News

Articles

The decision was based on results from the PROpel Phase III trial.

Lynparza Approved in UK as Combination Therapy for Treatment of Metastatic Castration-Resistant Prostate Cancer 

This approval makes the drug the first and only targeted medicine indicated to treat this population of children in Europe and the United States.

European Commission Approves Dupixent as First, Only Targeted Medicine for Children with Severe Atopic Dermatitis

Feliza Mirasol is the science editor for 

Sanofi intends to cut its US list price for Lantus (insulin glargine injection) by 78% and cap out-of-pocket costs at $35 for all patients with commercial insurance.

Sanofi Drops Lantus US List Price by 78%, Capping Out-of-Pocket Costs at $35

BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.

BioNTech and OncoC4 to Co-Develop mAb for Solid Tumor Indications

Grant Playter is the Assistant Editor for 

Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.

Stevanato Group and Recipharm to Collaborate on Pre-fillable Syringes for Soft Mist Inhaler

Evotec and Bristol Myers Squibb have announced progress in their strategic protein degradation partnership. 

Evotec and Bristol Myers Squibb Progress Strategic Partnership

Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs utilizing the PEDAL platform.

Predictive Oncology and Cancer Research Horizons Partner for Cancer Drug Development

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Sandoz to Build New Biologics Production Facility in Slovenia

The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.

Genuv and Celltrion Partner on Development of Novel Therapeutic Antibodies

Pfizer will acquire all outstanding shares of Seagen for a total of $43 billion.

Biopharma News